Analysis of the dynamics of expenditures on pharmaceutical support of population in ukraine, belarus republic and in european union
Description
Aim: comparative analysis the dynamics of changes in the indices of expenditures (%) on pharmaceutical provision of population from total health expenditure at the macroeconomic level in Ukraine, the Republic of Belarus (RB) and the countries of the European Union (EU).
Materials and methods. The studies used data from the World Health Organization and its Regional Office for Europe, as well as data from the legislative and regulatory framework regulating medical and pharmaceutical activities in Ukraine, the Republic of Belarus and the EU. Historical, analytical-comparative, systemic, logical, graphic, mathematical-statistical methods of scientific search and knowledge were used.
Results. It has been established that in the group of reference countries, the expenditures indicator (%) for the pharmaceutical provision of the population from the total spending on health during the period of 1990-2015 fluctuated in a wide range of values. The largest range of values was typical for Belarus (from 3.2 % in 1992 to 29.8 % in 2015), and the smallest for the EU countries (from 16.7 % in 2011 to 18.8 % according to 2003 data). Analyzing the dynamics of changes in this indicator, it was established that there was a tendency towards its decline across the EU and Ukraine, while in Belarus, on the contrary, it was increasing. Thus, in 2015, this indicator increased by 2.5 times, compared with the base data in the 1990 analysis. By the average value in order of magnitude of the indicator that was analyzed, the reference countries were located as follows: Ukraine (10.82 %); RB (14.87 %); EU countries (17.88 %).
Conclusions. A significant fluctuation in the values of expenditures (%) allocated for pharmaceutical provision of the population in total health expenditures in the group of countries that were studied was established. In addition, the unstable nature of changes in the indicator that was analyzed in Belarus indicates the need for further research in this direction
Files
10-14.pdf
Files
(377.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:b2920120f3ef7594955ef6a8823284ce
|
377.2 kB | Preview Download |
Additional details
References
- U prohrami «Dostupni liky» bere uchast blyzko 3 tys. aptek – Derzhkaznacheistvo (2019). Apteka, 2 (1173). Available at: https://www.apteka.ua/article/486357
- Nalichnye vyplaty semei na zdravookhranenie, v % ot obschikh zatrat na zdravookhranenie. VOZ. Evropeiskoe regionalnoe biuro. Available at: https://gateway.euro.who.int/ru/indicators/hfa_584-6860-private-households-out-of-pocket-payments-on-health-as-of-total-health-expenditure/visualizations/#id=19679
- Orhanizatsiia ekonomichnoho spivrobitnytstva ta rozvytku (OESR). Ministerstvo infrastruktury Ukrainy. Available at: https://mtu.gov.ua/content/organizaciya-ekonomichnogo-spivrobitnictva-ta-rozvitku-oesr.html
- Podpruzhnikov, Iu. V., Ishmukhametov, A. A., Nemchenko, A. S. et. al.; Ishmukhametov, A. A. (Ed.) (2015). Khresto-matiia farmacevticheskogo kachestva. Moscow: OOO «Gruppa Remedium», 432.
- Pharmacy workforce predicted to grow year on year in new report (2018). Press FIP – International Pharmaceutical Feder-ation. Available at: https://www.fip.org/press-releases?press=item&press-item=42
- Pharmacy Workforce Intelligence: Global Trends Report (2018). International Pharmaceutical Federation (FIP). Available at: https://fip.org/files/fip/PharmacyEducation/Workforce_Report_2018.pdf
- Fedina, E. A. (2015). Farmacevticheskaia pomosch kak aktualnoe nauchno-prakticheskoe napravlenie farmacii. Innovacionnaia nauka, 12 (2), 303–305.
- Fidler, A., Msisha, W. (2008). Governance in the pharmaceutical sector. Eurohealth, 14 (1), 25–29. Available at: http://www.lse.ac.uk/LSEHealthAndSocialCare/pdf/eurohealth/VOL14No1/FidlerMsisha.pdf
- Thompson, D. F. (2009). The Challenge of Conflict of Interest in Medicine. Zeitschrift Für Evidenz, Fortbildung Und Qualität Im Gesundheitswesen, 103 (3), 136–140. doi: http://doi.org/10.1016/j.zefq.2009.02.021
- Assessment of patient payment policies and projection of their efficiency, equity and quality effects: the case of Central and Eastern Europe (2007). ASSPRO CEE 2007. European Commission. Available at: https://cordis.europa.eu/project/rcn/ 88429/factsheet/en Last accessed: 01.01.2018
- Sommersguter-Reichmann, M., Wild, C., Stepan, A., Reichmann, G., Fried, A. (2018). Individual and Institutional Cor-ruption in European and US Healthcare: Overview and Link of Various Corruption Typologies. Applied Health Economics and Health Policy, 16 (3), 289–302. doi: http://doi.org/10.1007/s40258-018-0386-6
- Gagnon, M.-A. (2013). Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health. The Journal of Law, Medicine & Ethics, 41 (3), 571–580. doi: http://doi.org/10.1111/jlme.12066
- Evaluation of the Good Governance for Medicines programme (2004–2012): brief summary of findings (2013). World Health Or-ganization. Available at: http://www.who.int/medicines/areas/policy/goodgovernance/1426EMP_GoodGovernanceMedicinesreport.pdf?ua=1
- Lui, E., Ha, R., Truong, C. (2017). Applying the pharmaceutical care model to assess pharmacist services in a primary care set-ting. Canadian Pharmacists Journal / Revue Des Pharmaciens Du Canada, 150 (2), 90–93. doi: http://doi.org/10.1177/1715163517690538
- O registracii cen na LS (2018). Ukaz Prezidenta RB No. 345. 22.08 2018. Available at: http://president.gov.by/uploads/ documents/2018/345uk.pdf